10132-01-1Relevant articles and documents
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations
Khedr, Fathalla,Ibrahim, Mohamed-Kamal,Eissa, Ibrahim H.,Abulkhair, Hamada S.,El-Adl, Khaled
, (2021)
In the designed compounds, a new linker was inserted in the form of fragments with verified VEGFR-2 inhibitory potential, including an α,β-unsaturated ketonic fragment, pyrazole, and pyrimidine. Also, new distal hydrophobic moieties were attached to these
New 1,4-disubstituted phthalazines: Synthesis, structure and herbicidal evaluation
Bele, Constantin,Darabantu, Mircea
, p. 641 - 646 (2003)
The rapid synthesis of eighteen new 1,4-disubstituted phthalazines bearing an aryl or benzyl substituent at C-4 and a variety of aryloxy groups at C-1 is reported; full structural assignments are provided by NMR and MS data together with the biological evaluation for some representative terms of the series.
N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies
El-Adl, Khaled,Ibrahim, Mohamed-Kamal,Khedr, Fathalla,Abulkhair, Hamada S.,Eissa, Ibrahim H.
, (2020/12/14)
In accordance with the significant impetus of the discovery of potent vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors, herein, we report the design, synthesis, and anticancer evaluation of 12 new N-substituted-4-phenylphthalazin-1-amine
Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents
Eldehna, Wagdy M.,Almahli, Hadia,Al-Ansary, Ghada H.,Ghabbour, Hazem A.,Aly, Mohamed H.,Ismael, Omnia E.,Al-Dhfyan, Abdullah,Abdel-Aziz, Hatem A.
, p. 600 - 613 (2017/11/10)
Treatment of patients with triple-negative breast cancer (TNBC) is challenging due to the absence of well- defined molecular targets and the heterogeneity of such disease. In our endeavor to develop potent isatin-based anti-proliferative agents, we utiliz